NasdaqCM - Nasdaq Real Time Price USD

Citius Oncology, Inc. (CTOR)

0.8755

-0.0145

(-1.63%)

At close: May 21 at 4:00:01 PM EDT

Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal second quarter ended March 31, 2025.

PR Newswire 7 days ago

CTOR
-1.63%
Citius Oncology, Inc. (NASDAQ:CTOR) Is Expected To Breakeven In The Near Future

We feel now is a pretty good time to analyse Citius Oncology, Inc.'s ( NASDAQ:CTOR ) business as it appears the company...

Simply Wall St. 14 days ago

CTOR
-1.63%
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), today announced that LYMPHIR™ (denileukin diftitox-cxdl) has been assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code (J9161) by the Centers for Medicare & Medicaid Services (CMS).

PR Newswire 3 months ago

CTOR
-1.63%

CTXR
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Management is focused on making LYMPHIR available to patients as quickly as possible, with preparations underway for launch in the first half

PR Newswire 4 months ago

CTXR

CTOR
-1.63%
Citius Oncology to explore strategic alternatives

Citius Oncology (CTOR), a majority-owned subsidiary of Citius Pharmaceuticals (CTXR), announced that it has retained Jefferies (JEF) as its exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value. The engagement of Jefferies underscores Citius Oncology’s commitment to exploring all avenues for enhancing its strategic positioning and advancing its mission to improve patient outcomes in oncology. Strategic alternatives under consideration ma

TipRanks 4 months ago

JEF

CTOR
-1.63%

CTXR
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

Citius Oncology, Inc. ("Citius Oncology" or "the Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value.

PR Newswire 4 months ago

CTXR

CTOR
-1.63%
Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital

D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which is close to commercializing Lymphir, an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma, the analyst tells investors in a research note. The firm believes that as Lymphir launches, it will become a value driver for its parent, Citius. Oncology drug Lymphir has achieved significant milestones in its develo

TipRanks 4 months ago

CTXR

CTOR
-1.63%
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024.

PR Newswire 4 months ago

CTOR
-1.63%

CTXR
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024.

PR Newswire 4 months ago

CTOR
-1.63%
Citius Oncology, Inc.'s (NASDAQ:CTOR) Path To Profitability

We feel now is a pretty good time to analyse Citius Oncology, Inc.'s ( NASDAQ:CTOR ) business as it appears the company...

Simply Wall St. 5 months ago

CTOR
-1.63%
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced that Chairman and CEO Leonard Mazur will present and host one-on-one investor meetings at the H.C. Wainwright & Co. 26th Annual Global Investment Conference taking place September 9–11, 2024, in New York City.

PR Newswire 8 months ago

CTXR

CTOR
-1.63%

Performance Overview

Return	CTOR	S&P 500 (^GSPC)
YTD	-23.87%	-0.63%
1-Year	-92.23%	+9.83%
3-Year	-91.32%	+49.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Citius Oncology, Inc. (CTOR)

Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

Citius Oncology, Inc. (NASDAQ:CTOR) Is Expected To Breakeven In The Near Future

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

Citius Oncology to explore strategic alternatives

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Citius Oncology, Inc.'s (NASDAQ:CTOR) Path To Profitability

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Performance Overview